| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SLV from our risk checks.
Selvita S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł66.20 |
| 52 Week High | zł76.50 |
| 52 Week Low | zł55.40 |
| Beta | 0.056 |
| 1 Month Change | -4.89% |
| 3 Month Change | 12.20% |
| 1 Year Change | -3.36% |
| 3 Year Change | -10.78% |
| 5 Year Change | n/a |
| Change since IPO | 215.24% |
Recent News & Updates
Earnings Report: Selvita S.A. Missed Revenue Estimates By 7.1%
May 26
Selvita's (WSE:SLV) Solid Earnings May Rest On Weak Foundations
Apr 03Selvita S.A. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Apr 01Recent updates
Earnings Report: Selvita S.A. Missed Revenue Estimates By 7.1%
May 26Selvita's (WSE:SLV) Solid Earnings May Rest On Weak Foundations
Apr 03Selvita S.A. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Apr 01Selvita S.A. (WSE:SLV) Analysts Just Cut Their EPS Forecasts Substantially
Oct 07We Think Selvita (WSE:SLV) Can Stay On Top Of Its Debt
Sep 28Here's Why Selvita (WSE:SLV) Has Caught The Eye Of Investors
Jun 02Selvita (WSE:SLV) Seems To Use Debt Quite Sensibly
Jun 09These 4 Measures Indicate That Selvita (WSE:SLV) Is Using Debt Reasonably Well
Feb 23If You Like EPS Growth Then Check Out Selvita (WSE:SLV) Before It's Too Late
Mar 31Here's What Selvita S.A.'s (WSE:SLV) Shareholder Ownership Structure Looks Like
Feb 25Here's Why We Don't Think Selvita's (WSE:SLV) Statutory Earnings Reflect Its Underlying Earnings Potential
Jan 22
Is Now The Time To Put Selvita (WSE:SLV) On Your Watchlist?
Dec 25Did You Miss Selvita's (WSE:SLV) Impressive 113% Share Price Gain?
Dec 02Shareholder Returns
| SLV | PL Life Sciences | PL Market | |
|---|---|---|---|
| 7D | -8.1% | -3.3% | -2.7% |
| 1Y | -3.4% | -4.7% | 24.5% |
Return vs Industry: SLV exceeded the Polish Life Sciences industry which returned -7.7% over the past year.
Return vs Market: SLV underperformed the Polish Market which returned 26.9% over the past year.
Price Volatility
| SLV volatility | |
|---|---|
| SLV Average Weekly Movement | 4.3% |
| Life Sciences Industry Average Movement | 5.7% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PL Market | 9.2% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: SLV has not had significant price volatility in the past 3 months.
Volatility Over Time: SLV's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 886 | Boguslaw Sieczkowski | selvita.com |
Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, analytical and solid state chemistry, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, inflammation, and fibrosis.
Selvita S.A. Fundamentals Summary
| SLV fundamental statistics | |
|---|---|
| Market cap | zł1.22b |
| Earnings (TTM) | zł65.30m |
| Revenue (TTM) | zł337.26m |
18.6x
P/E Ratio3.6x
P/S RatioIs SLV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLV income statement (TTM) | |
|---|---|
| Revenue | zł337.26m |
| Cost of Revenue | zł68.59m |
| Gross Profit | zł268.66m |
| Other Expenses | zł203.37m |
| Earnings | zł65.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 25, 2024
| Earnings per share (EPS) | 3.56 |
| Gross Margin | 79.66% |
| Net Profit Margin | 19.36% |
| Debt/Equity Ratio | 39.2% |
How did SLV perform over the long term?
See historical performance and comparison